Kangji Medical Holdings Limited: history, ownership, mission, how it works & makes money

From its launch in August 2004 as a high‑tech maker of minimally invasive surgical instruments, Kangji Medical built rapid domestic and international traction-listing on the Hong Kong Main Board in June 2020 (9997.HK) after its products reached over 3,000 hospitals (including more than 1,000 Grade IIIA hospitals) and expanded to 33 overseas markets by 2020; by the first half of 2025 the company reported revenue of RMB 496.6 million (up 8.3%) driven by disposable consumables even as net profit attributable to owners fell 7.0%, and it operated a broad distribution network serving over 3,500 hospitals with 500+ domestic distributors while offering disposable trocars, polymer clips, ultrasonic scalpels and reusable 4K endoscopic systems certified to ISO 9001/14001/45001 and EN ISO 13485 standards; ownership shifted from Chairman Zhong Ming and his spouse holding 52.98% in August 2025 to a consortium led privatization supported by TPG, NewQuest V and Al‑Rayyan Holding that was completed in December 2025, making Kangji Medical a wholly owned subsidiary and repositioning its capital structure (TopCo ownership: Zhong & spouse 40%, TPG ~24.38%, NewQuest 4.56%, Al‑Rayyan 20.36% with the consortium controlling 74.75%) as it pursues a mission to provide high‑quality products, embrace innovation, and expand global market share

Kangji Medical Holdings Limited (9997.HK): Intro

• Founded: August 2004
• Primary focus: Minimally invasive surgical instruments & accessories (MISIA)
• Stock code (historical): 9997.HK - Listed on HKEX Main Board in June 2020
• Privatized: Proposal announced August 2025; transaction completed December 2025

• Product R&D and manufacturing: develops disposable and reusable MIS instruments, leveraging in‑house engineering and clinical partnerships to iterate devices.
• Direct hospital sales and distributor channels: supplies hospitals directly (notably tertiary Grade IIIA hospitals) and uses domestic distributors and overseas partners for export markets.
• Consumables & recurring revenue: high-margin recurring revenue from disposable accessories and single‑use instruments that accompany capital devices.
• Service & training: surgical training, device maintenance, and clinical support generate ancillary revenue and strengthen adoption.
• Regulatory & quality leverage: approvals and certifications for target markets increase addressable hospital base and pricing power.

• Hospital reach in China: >3,000 hospitals
• Tier of hospital customers: >1,000 Grade IIIA hospitals
• International reach: 33 countries/regions outside China
• Corporate events: HKEX listing (June 2020); privatization completed (Dec 2025)

• Revenue mix: product sales (capital devices + consumables) dominate; consumables offer recurring, higher-margin streams.
• Gross margin drivers: product mix (disposables vs capital equipment), production scale, and procurement of medical‑grade components.
• Growth levers: deeper penetration of Grade IIIA hospitals, expansion into additional international markets, and launch of new MIS product lines.
• Capital structure shift: public financing post-IPO (2020) supported expansion; privatization (2025) shifted ownership and removed public reporting obligations.

• Chairman and lead privatization proponent: Zhong Ming
• Privatization consortium: Zhong Ming + TPG + Qatar Investment Authority (QIA)
• Post-privatization status: wholly-owned subsidiary of the consortium; shares withdrawn from the Hong Kong Stock Exchange
• Further corporate materials and positioning: Mission Statement, Vision, & Core Values (2026) of Kangji Medical Holdings Limited.

Kangji Medical Holdings Limited (9997.HK): History

• As of August 2025, Kangji Medical was controlled by Chairman Zhong Ming and his spouse, Ms. Shentu, who together held 52.98% of the company's shares.
• The August 2025 privatization proposal was led by a consortium comprising Zhong Ming and Ms. Shentu, TPG, NewQuest V, and Al‑Rayyan Holding.
• The consortium collectively controlled 74.75% of Kangji Medical's shares, enabling the privatization.
• Following completion of the privatization in December 2025, Kangji Medical's shares were withdrawn from the Hong Kong Stock Exchange.

• How it works - core operations: design, manufacture and distribution of medical devices; supply of consumables; after‑sales service and clinical support; strategic partnerships with hospitals and distributors.
• How it makes money - revenue streams include product sales (capital equipment and consumables), recurring service and maintenance contracts, warranty/extended service revenues, and licensing/technology collaborations with healthcare providers and OEM partners.
• Strategic ownership intent: the post‑privatization structure concentrated strategic control with the founding family (40% via TopCo) while bringing in private equity partners (TPG, NewQuest V, Al‑Rayyan) to provide capital, network access and operational scaling support.

Kangji Medical Holdings Limited (9997.HK): Ownership Structure

• Mission: To provide physicians with high-quality products and services, dedicated to improving people's health.
• Vision: To become the world's leading medical device enterprise.
• Core values:
  • Customers First - prioritize clinician and patient needs in product design and service delivery.
  • Embrace Innovation - continuous R&D and adoption of advanced materials and digital technologies.
  • Demonstrate Integrity - compliance, clinical evidence, and ethical interactions across markets.
  • Be Proactive - market-driven product pipelines and proactive regulatory strategy.

• Founded to serve surgical and interventional markets, Kangji Medical has expanded from regional OEM/ODM work into proprietary branded devices and consumables targeting hospitals and specialist clinics.
• Key milestones include product line expansion into orthopedics and cardiovascular interventional devices, establishment of an in-house R&D center, and progressive international distribution agreements.
• Revenue model combines direct sales, distributor partnerships, and contract manufacturing for third parties.

• Product segments: implantable devices, single-use surgical consumables, and diagnostic/accessory products sold to hospitals and distributors.
• Channels: direct hospital tenders, national distributors, international export partners, and OEM/ODM contracts.
• Revenue drivers:
  • Sales growth from new product launches and geographic expansion.
  • Recurring revenue from consumables and post-operative disposables.
  • Contract manufacturing margins from OEM/ODM clients.
• Cost structure emphasizes manufacturing scale, quality control, and R&D spending to maintain clinical competitiveness.

• Scaling higher-margin proprietary devices and expanding recurring consumables improves EBITDA conversion.
• Investing in regulatory approvals (CE, FDA pathways) to unlock advanced-market pricing and distribution.
• Strengthening hospital tender capabilities and long-term contracts with group purchasing organizations.
• Pursuing targeted M&A or technology partnerships to fill pipeline gaps and accelerate international presence.

Kangji Medical Holdings Limited (9997.HK): Mission and Values

• Obstetrics and gynecology
• General surgery
• Urology
• Thoracic surgery

• Disposable consumables - primary revenue drivers: disposable trocars, polymer ligation clips, disposable electrocoagulation forceps and ultrasonic scalpels. These are single-use items designed for cost-efficiency and sterility.
• Reusable systems - higher-margin durable devices: 4K endoscopic camera systems, laparoscopic instrument handles and select reusable forceps and retractors. Reusable equipment supports recurring revenue through service, parts and accessories.
• Integrated solutions - bundled offerings of disposable and reusable products plus procedure-specific kits for hospital procurement and surgeon preference.

• Domestic distribution network: multi-tiered approach through regional distributors, direct hospital tenders and key account management for tertiary hospitals in China.
• Overseas channels: exports to select international markets via distributors and direct institutional sales; participation in international exhibitions and regulatory approvals to expand footprint.

• ISO 9001:2015 - quality management system
• ISO 14001:2015 - environmental management
• ISO 45001:2018 - occupational health and safety
• EN ISO 13485:2016 - medical device quality management
• CE certification - conformity for European market access

• Product mix: consumables typically account for the majority of units sold; reusable systems account for a meaningful share of revenue by value.
• Customer base: hospitals (public and private), surgical centers, distributors; expanding presence in tertiary hospitals is a strategic priority.
• Manufacturing: vertically integrated production lines for injection-molded plastic disposables and precision metal components for reusable devices; scale enables unit-cost reductions.

• R&D and regulatory clearance: new device design → clinical evaluation → quality certification (ISO/CE) → registration for hospital procurement.
• Commercial engagement: demonstrateability in live surgeries or simulated lab settings → pilot supply to key opinion leaders → inclusion in hospital formularies and surgical kits.
• Post-sale support: warranty, technical training for reusable systems, replacement parts and consumable resupply contracts.

• Consumables: lower gross margin per unit but repeatable revenue and predictable demand tied to surgical procedure volumes.
• Reusable equipment: higher gross margin per sale, longer sales cycles, and dependency on capital budget approvals by hospitals.

• Expanding product portfolio across the four core specialties to increase share of procedure-related spend.
• Deepening penetration in tertiary hospitals and securing long-term supply agreements.
• International expansion supported by maintained CE and relevant overseas registrations.
• Operational scale and quality systems to defend pricing and meet tender requirements.

Kangji Medical Holdings Limited (9997.HK): How It Works

• Core product lines: disposable consumables (catheters, trocars, sheaths, single‑use accessories) and reusable surgical instruments.
• Sales channels: direct sales to hospitals, third‑party distributors, and export partners.
• Customer base: clinical departments in cardiology, interventional radiology and related surgical specialties.

• Sale of disposable consumables - high gross margin and repeat purchase frequency drive steady cash flow.
• Sale and refurbishment of reusable instruments - lower frequency but higher per‑unit value and aftermarket service income.
• Channel fees, logistics and ancillary accessory sales through a broad distribution network.
• Geographic mix allows diversification of demand and pricing strategies between domestic (mainland China) and international markets.

• Product demand trends (e.g., adoption of minimally invasive procedures).
• Operational efficiency (manufacturing yields, procurement costs, inventory management).
• Pricing and product mix (share of disposables vs reusable instruments).
• Competition from domestic peers and multinational medical device companies.
• Performance of associates and non‑operating income (affecting net profit).

• Broad hospital coverage creates repeatable consumables demand; disposables represent a growing portion of sales and supported the 8.3% revenue increase in H1 2025.
• Over 500 domestic distributors and direct penetration into over 3,500 hospitals lower customer acquisition costs and enable scale.
• Export sales diversify currency and market risk while exposing the company to regulatory and competitive dynamics abroad.

Kangji Medical Holdings Limited (9997.HK): How It Makes Money

• Core revenue streams:
  • Implants & prostheses (orthopedics & spine)
  • Surgical instruments and implant systems
  • Consumables and ancillary surgical products
  • Service, training and product support for hospital customers
• Channels to market:
  • Direct sales to hospitals (tender & direct procurement)
  • Domestic distributors (over 500 partners)
  • International distributors and export markets (presence in 80+ countries)

• Greater reinvestment in R&D to develop higher-margin, innovative implant systems and digital surgical solutions.
• Operational enhancements aimed at improving gross margins via localized manufacturing scale and supply-chain optimization.
• Acceleration of international expansion to capture higher-growth markets and diversify revenue by geography.
• Deeper partnerships with hospital groups to increase share-of-wallet through bundled solutions, training and after-sales services.

• Governance alignment under Chairman Zhong Ming with strategic capital from TPG and QIA to support multi-year projects.
• Freedom to prioritize long-term investments over quarterly public reporting pressures, notably in R&D and capital expenditures.
• Expected competitive gains through product innovation and scale, supporting market-share growth in both domestic and international markets.